Home Cart 0 Sign in  
X

[ CAS No. 459-23-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 459-23-4
Chemical Structure| 459-23-4
Chemical Structure| 459-23-4
Structure of 459-23-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 459-23-4 ]

Related Doc. of [ 459-23-4 ]

Alternatived Products of [ 459-23-4 ]

Product Details of [ 459-23-4 ]

CAS No. :459-23-4 MDL No. :MFCD00133101
Formula : C7H6FNO Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 139.13 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 459-23-4 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 35.78
TPSA : 32.59 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.71 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.63
Log Po/w (XLOGP3) : 2.03
Log Po/w (WLOGP) : 2.05
Log Po/w (MLOGP) : 1.77
Log Po/w (SILICOS-IT) : 2.1
Consensus Log Po/w : 1.92

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.36
Solubility : 0.608 mg/ml ; 0.00437 mol/l
Class : Soluble
Log S (Ali) : -2.34
Solubility : 0.633 mg/ml ; 0.00455 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.17
Solubility : 0.949 mg/ml ; 0.00682 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 3.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.59

Safety of [ 459-23-4 ]

Signal Word:Danger Class:4.1,6.1
Precautionary Statements:P240-P210-P241-P280-P370+P378-P501-P261-P270-P271-P264-P337+P313-P305+P351+P338-P361+P364-P332+P313-P301+P310+P330-P302+P352+P312-P304+P340+P311-P403+P233-P405 UN#:2926
Hazard Statements:H228-H301+H311+H331-H315-H319 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 459-23-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 459-23-4 ]
  • Downstream synthetic route of [ 459-23-4 ]

[ 459-23-4 ] Synthesis Path-Upstream   1~9

  • 1
  • [ 459-23-4 ]
  • [ 107-19-7 ]
  • [ 206055-89-2 ]
Reference: [1] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 4227 - 4230
[2] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 5, p. 1349 - 1351
[3] Chemical Papers, 2015, vol. 69, # 11, p. 1500 - 1511
[4] Patent: CN105801509, 2016, A, . Location in patent: Paragraph 0044; 0048; 0049
[5] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5440 - 5448
[6] Ultrasonics Sonochemistry, 2017, vol. 36, p. 343 - 353
[7] Patent: CN106749218, 2017, A, . Location in patent: Paragraph 0066; 0067
  • 2
  • [ 459-23-4 ]
  • [ 6175-54-8 ]
  • [ 206055-89-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 12, p. 2674 - 2677
  • 3
  • [ 459-23-4 ]
  • [ 206055-89-2 ]
Reference: [1] Synthesis, 2002, # 12, p. 1663 - 1668
  • 4
  • [ 459-23-4 ]
  • [ 206055-89-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 15, p. 4652 - 4657
[2] European Journal of Medicinal Chemistry, 2017, vol. 128, p. 25 - 35
  • 5
  • [ 459-23-4 ]
  • [ 1018297-63-6 ]
Reference: [1] Patent: US2013/102778, 2013, A1,
[2] Patent: US2013/102778, 2013, A1,
[3] Patent: WO2013/57123, 2013, A1,
[4] Patent: WO2013/57123, 2013, A1,
[5] Patent: WO2013/57124, 2013, A1,
[6] Patent: WO2013/57124, 2013, A1,
[7] Patent: WO2013/57124, 2013, A1,
[8] Patent: WO2013/57124, 2013, A1,
[9] Patent: US2013/172329, 2013, A1,
[10] Patent: US2013/172329, 2013, A1,
[11] Patent: US2013/172329, 2013, A1,
[12] Patent: US2013/172329, 2013, A1,
[13] Patent: EP2792360, 2014, A1,
[14] Patent: EP2792360, 2014, A1,
[15] Patent: EP2792360, 2014, A1,
[16] Patent: EP2792360, 2014, A1,
  • 6
  • [ 2723-42-4 ]
  • [ 459-23-4 ]
  • [ 954230-39-8 ]
YieldReaction ConditionsOperation in experiment
95%
Stage #1: With N-chloro-succinimide In N,N-dimethyl-formamide at 20℃; for 1.5 h;
Stage #2: at 20℃; for 28 h;
Step b)
3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester
To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was added portionwise within 5 minutes at 15 to 20° C. N-chlorosuccinimide (1.36 g, 10.0 mmol) and the resulting mixture was stirred at room temperature for 90 minutes.
The yellow solution (containing N-Hydroxy-4-fluoro-benzenecarboximidoyl chloride) was then treated within 2 minutes at room temperature with a solution of ethyl-3-(1-pyrrolidino)crotonate (1.89 g, 10.0 mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours.
The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4*25 mL).
The combined organic layers were washed with 1 M HCl (2*25 mL) and water (2*25 mL), dried over Na2SO4 and subsequently concentrated to dryness (45° C./25 mbar) to afford 2.37 g (95percent) of the title compound as a brownish solid with a purity of 100percent (by GC) and 97percent (by HPLC).
95%
Stage #1: With N-chloro-succinimide In N,N-dimethyl-formamide at 15 - 20℃; for 1.58333 h;
Stage #2: at 20℃; for 28 h;
Step b) 3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxyric acid ethyl ester To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was added portionwise within 5 minutes at 15 to 20°C N-chlorosuccinimide (1.36 g, 10.0 mmol) and the resulting mixture was stirred at room temperature for 90 minutes. The yellow solution (containing N-Hydroxy-4-fluoro-benzenecarboximidoyl chloride) was then treated within 2 minutes at room temperature with a solution of ethyl-3-(l-pyrrolidino)crotonate (1.89 g, 10.0 mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours. The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4x25 mL). The combined organic layers were washed with 1 M HCl (2x25 mL) and water (2x25 mL), dried over Na2S04 and subsequently concentrated to dryness (45°C/25 mbar) to afford 2.37 g (95percent) of the title compound as a brownish solid with a purity of 100percent (by GC) and 97percent (by HPLC).
95%
Stage #1: With N-chloro-succinimide In N,N-dimethyl-formamide at 15 - 20℃; for 1.58333 h;
Stage #2: at 20℃; for 28 h;
Step b)
3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester
To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was added portionwise within 5 minutes at 15 to 20° C. N-chlorosuccinimide (1.36 g, 10.0 mmol) and the resulting mixture was stirred at room temperature for 90 minutes.
The yellow solution (containing N-Hydroxy-4-fluoro-benzenecarboximidoyl chloride) was then treated within 2 minutes at room temperature with a solution of ethyl-3-(1-pyrrolidino)crotonate (1.89 g, 10.0 mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours.
The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4*25 mL).
The combined organic layers were washed with 1 M HCl (2*25 mL) and water (2*25 mL), dried over Na2SO4 and subsequently concentrated to dryness (45° C./25 mbar) to afford 2.37 g (95percent) of the title ester as a brownish solid with a purity of 100percent (by GC) and 97percent (by HPLC).
Reference: [1] Patent: US2013/102778, 2013, A1, . Location in patent: Paragraph 0220
[2] Patent: WO2013/57123, 2013, A1, . Location in patent: Page/Page column 31
[3] Patent: US2013/172329, 2013, A1, . Location in patent: Paragraph 0257
  • 7
  • [ 54716-02-8 ]
  • [ 459-23-4 ]
  • [ 954230-39-8 ]
YieldReaction ConditionsOperation in experiment
95%
Stage #1: With N-chloro-succinimide In N,N-dimethyl-formamide at 15 - 20℃; for 1.58333 h;
Stage #2: at 20℃; for 28 h;
Step b) 3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester: [0176] To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was added portionwise within 5 minutes at 15 to 20°C N-chlorosuccinimide (1.36 g, 10.0 mmol) and the resulting mixture was stirred at room temperature for 90 minutes. The yellow solution (containing N-Hydroxy-4-fluoro-benzenecarboximidoyl chloride) was then treated within 2 minutes at room temperature with a solution of ethyl-3-(1-pyrrolidino)crotonate (1.89 g, 10.0 mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours. The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4x25 mL). The combined organic layers were washed with 1 M HCl (2x25 mL) and water (2x25 mL), dried over Na2S04 and subsequently concentrated to dryness (45°C/25 mbar) to afford 2.37 g (95percent) of the title ester as a brownish solid with a purity of 100percent (by GC) and 97percent (by HPLC).
Reference: [1] Patent: EP2792360, 2014, A1, . Location in patent: Paragraph 0175-0176
  • 8
  • [ 459-23-4 ]
  • [ 954230-39-8 ]
Reference: [1] Patent: WO2013/57124, 2013, A1,
[2] Patent: WO2013/57124, 2013, A1,
[3] Patent: US2013/172329, 2013, A1,
[4] Patent: EP2792360, 2014, A1,
  • 9
  • [ 459-23-4 ]
  • [ 1159600-41-5 ]
Reference: [1] Patent: US2013/102778, 2013, A1,
[2] Patent: US2013/102778, 2013, A1,
[3] Patent: WO2013/57123, 2013, A1,
[4] Patent: WO2013/57123, 2013, A1,
[5] Patent: WO2013/57123, 2013, A1,
[6] Patent: WO2013/57123, 2013, A1,
[7] Patent: WO2013/57124, 2013, A1,
[8] Patent: WO2013/57124, 2013, A1,
[9] Patent: WO2013/57124, 2013, A1,
[10] Patent: WO2013/57124, 2013, A1,
[11] Patent: WO2013/57124, 2013, A1,
[12] Patent: WO2013/57124, 2013, A1,
[13] Patent: WO2013/57124, 2013, A1,
[14] Patent: WO2013/57124, 2013, A1,
[15] Patent: WO2013/57124, 2013, A1,
[16] Patent: WO2013/57124, 2013, A1,
[17] Patent: WO2013/57124, 2013, A1,
[18] Patent: WO2013/57124, 2013, A1,
[19] Patent: WO2013/57124, 2013, A1,
[20] Patent: WO2013/57124, 2013, A1,
[21] Patent: WO2013/57124, 2013, A1,
[22] Patent: WO2013/57124, 2013, A1,
[23] Patent: US2013/172329, 2013, A1,
[24] Patent: US2013/172329, 2013, A1,
[25] Patent: US2013/172329, 2013, A1,
[26] Patent: US2013/172329, 2013, A1,
[27] Patent: US2013/172329, 2013, A1,
[28] Patent: US2013/172329, 2013, A1,
[29] Patent: US2013/172329, 2013, A1,
[30] Patent: US2013/172329, 2013, A1,
[31] Patent: US2013/172329, 2013, A1,
[32] Patent: US2013/172329, 2013, A1,
[33] Patent: US2013/172329, 2013, A1,
[34] Patent: US2013/172329, 2013, A1,
[35] Patent: US2013/172329, 2013, A1,
[36] Patent: US2013/172329, 2013, A1,
[37] Patent: US2013/172329, 2013, A1,
[38] Patent: US2013/172329, 2013, A1,
[39] Patent: EP2792360, 2014, A1,
[40] Patent: EP2792360, 2014, A1,
[41] Patent: EP2792360, 2014, A1,
[42] Patent: EP2792360, 2014, A1,
[43] Patent: EP2792360, 2014, A1,
[44] Patent: EP2792360, 2014, A1,
[45] Patent: EP2792360, 2014, A1,
[46] Patent: EP2792360, 2014, A1,
[47] Patent: EP2792360, 2014, A1,
[48] Patent: EP2792360, 2014, A1,
[49] Patent: EP2792360, 2014, A1,
[50] Patent: EP2792360, 2014, A1,
[51] Patent: EP2792360, 2014, A1,
[52] Patent: EP2792360, 2014, A1,
[53] Patent: EP2792360, 2014, A1,
[54] Patent: EP2792360, 2014, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 459-23-4 ]

Fluorinated Building Blocks

Chemical Structure| 154238-36-5

[ 154238-36-5 ]

(E)-3-Fluorobenzaldehyde oxime

Similarity: 0.97

Chemical Structure| 677728-83-5

[ 677728-83-5 ]

3,5-Difluorobenzaldehyde oxime

Similarity: 0.94

Chemical Structure| 24652-66-2

[ 24652-66-2 ]

(E)-2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 451-79-6

[ 451-79-6 ]

2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 247092-11-1

[ 247092-11-1 ]

2,4-Difluorobenzaldehyde oxime

Similarity: 0.85

Aryls

Chemical Structure| 154238-36-5

[ 154238-36-5 ]

(E)-3-Fluorobenzaldehyde oxime

Similarity: 0.97

Chemical Structure| 677728-83-5

[ 677728-83-5 ]

3,5-Difluorobenzaldehyde oxime

Similarity: 0.94

Chemical Structure| 24652-66-2

[ 24652-66-2 ]

(E)-2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 451-79-6

[ 451-79-6 ]

2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 247092-11-1

[ 247092-11-1 ]

2,4-Difluorobenzaldehyde oxime

Similarity: 0.85

Oximes

Chemical Structure| 154238-36-5

[ 154238-36-5 ]

(E)-3-Fluorobenzaldehyde oxime

Similarity: 0.97

Chemical Structure| 677728-83-5

[ 677728-83-5 ]

3,5-Difluorobenzaldehyde oxime

Similarity: 0.94

Chemical Structure| 24652-66-2

[ 24652-66-2 ]

(E)-2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 451-79-6

[ 451-79-6 ]

2-Fluorobenzaldehyde oxime

Similarity: 0.88

Chemical Structure| 247092-11-1

[ 247092-11-1 ]

2,4-Difluorobenzaldehyde oxime

Similarity: 0.85